Skip to main content

Advertisement

Table 1 Comparison of demographics and clinical features of leprosy patient both prior to and after implementation of the safety tool

From: Evaluation of safety tool for ambulatory leprosy patients at risk of adverse outcome

Patient Characteristics Pre-implementation (n = 8) Post-implementation (n = 9)
Age, years, median (range) 17 (3–81 yrs) 50 (26–73 yrs)
Male to Female Ratio 3: 5 7: 2
Region of Acquisition
 Indian sub-continent 7 (87.5%) 4 (44.4%)
 Southeast Asia 1 (12.5%) 4 (44.4%)
 Africa 0 1 (11.1%)
Paucibacillarya Leprosy 7 (87.5%) 9 (100%)
Multibacillaryb Leprosy 1 (12.5%) 0
Occurrence of Reactionc
 At presentation 1 (12.5) 5 (55.6%)
 During treatment 1 (12.5%) 8 (88.9%)
 Following treatment 0 1 (11.1%)
Loss to follow-up 5 (62.5%) 0
  1. a≤5 skin lesions and absence of acid-fast bacilli on slit skin examination or biopsy
  2. b> 5 skin lesions with acid-fast bacilli noted on slit skin examination or biopsy
  3. cacute inflammatory episodes due to immunological response to Mycobacterium leprae, and characterized by increasing pain, swelling, and tenderness of skin lesions and worsening neuropathy in Type 1 reactions; and tender crops of skin nodules, fever, and systemic signs of end-organ involvement in Type 2 reactions